JP2015517976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517976A5 JP2015517976A5 JP2014557773A JP2014557773A JP2015517976A5 JP 2015517976 A5 JP2015517976 A5 JP 2015517976A5 JP 2014557773 A JP2014557773 A JP 2014557773A JP 2014557773 A JP2014557773 A JP 2014557773A JP 2015517976 A5 JP2015517976 A5 JP 2015517976A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- ring
- attached
- carbon atom
- heteroatoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052799 carbon Inorganic materials 0.000 claims description 141
- 125000005842 heteroatoms Chemical group 0.000 claims description 116
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 112
- 125000003118 aryl group Chemical group 0.000 claims description 70
- 229910052757 nitrogen Inorganic materials 0.000 claims description 68
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 64
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 64
- 125000001072 heteroaryl group Chemical group 0.000 claims description 46
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 36
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 36
- 125000002252 acyl group Chemical group 0.000 claims description 32
- 125000003342 alkenyl group Chemical group 0.000 claims description 32
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 32
- 125000000304 alkynyl group Chemical group 0.000 claims description 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 32
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 32
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 32
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 claims description 32
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 32
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 32
- 150000002829 nitrogen Chemical group 0.000 claims description 32
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 32
- 125000005251 aryl acyl group Chemical group 0.000 claims description 31
- -1 arylacyloxy Chemical group 0.000 claims description 30
- 125000005253 heteroarylacyl group Chemical group 0.000 claims description 25
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 24
- 125000001188 haloalkyl group Chemical group 0.000 claims description 24
- 150000001721 carbon Chemical class 0.000 claims description 21
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 125000004442 acylamino group Chemical group 0.000 claims description 16
- 125000004423 acyloxy group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000003282 alkyl amino group Chemical group 0.000 claims description 16
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 16
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 16
- 125000004414 alkyl thio group Chemical group 0.000 claims description 16
- 125000001769 aryl amino group Chemical group 0.000 claims description 16
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 16
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 16
- 125000005110 aryl thio group Chemical group 0.000 claims description 16
- 125000004104 aryloxy group Chemical group 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 16
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 16
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 16
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- 229910021386 carbon form Inorganic materials 0.000 claims description 11
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 208000001756 Virus Disease Diseases 0.000 claims description 7
- 241000712891 Arenavirus Species 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 206010047461 Viral infection Diseases 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 230000017613 viral reproduction Effects 0.000 claims description 6
- YAZYNFTXSMINHB-UHFFFAOYSA-N 1-(4-ethoxyphenyl)-N-[(4-ethylphenyl)methyl]indol-5-amine Chemical compound C1=CC(OCC)=CC=C1N1C2=CC=C(NCC=3C=CC(CC)=CC=3)C=C2C=C1 YAZYNFTXSMINHB-UHFFFAOYSA-N 0.000 claims description 4
- ILMTZAKFHNSRKU-UHFFFAOYSA-N 1-(4-ethoxyphenyl)-N-[(4-ethylphenyl)methyl]pyrrolo[2,3-b]pyridin-5-amine Chemical compound C1=CC(OCC)=CC=C1N1C2=NC=C(NCC=3C=CC(CC)=CC=3)C=C2C=C1 ILMTZAKFHNSRKU-UHFFFAOYSA-N 0.000 claims description 4
- SUDQKMASUNBASY-UHFFFAOYSA-N 3-(4-ethoxyphenyl)-N-[(4-ethylphenyl)methyl]-1H-indol-6-amine Chemical compound C1=CC(OCC)=CC=C1C1=CNC2=CC(NCC=3C=CC(CC)=CC=3)=CC=C12 SUDQKMASUNBASY-UHFFFAOYSA-N 0.000 claims description 4
- IFWCJRJDBZFBFC-UHFFFAOYSA-N 3-(4-ethoxyphenyl)-N-[(4-ethylphenyl)methyl]imidazo[1,2-a]pyridin-7-amine Chemical compound C1=CC(OCC)=CC=C1C1=CN=C2N1C=CC(NCC=1C=CC(CC)=CC=1)=C2 IFWCJRJDBZFBFC-UHFFFAOYSA-N 0.000 claims description 4
- YCELCDDRHIAHGC-UHFFFAOYSA-N 3-[(4-ethoxyphenyl)methyl]-N-[(4-ethylphenyl)methyl]imidazo[4,5-b]pyridin-6-amine Chemical compound C1=CC(OCC)=CC=C1CN1C2=NC=C(NCC=3C=CC(CC)=CC=3)C=C2N=C1 YCELCDDRHIAHGC-UHFFFAOYSA-N 0.000 claims description 4
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atoms Chemical class 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000004430 oxygen atoms Chemical group O* 0.000 claims description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 3
- 241000736032 Sabia <angiosperm> Species 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229960005486 vaccines Drugs 0.000 claims description 3
- DBNZTRPIBJSUIX-WAYWQWQTSA-N 2-[4-[(Z)-2-[1-(4-propan-2-yloxyphenyl)benzimidazol-5-yl]ethenyl]phenyl]propan-2-ol Chemical compound C1=CC(OC(C)C)=CC=C1N1C2=CC=C(\C=C/C=3C=CC(=CC=3)C(C)(C)O)C=C2N=C1 DBNZTRPIBJSUIX-WAYWQWQTSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229940047124 Interferons Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 11
- TVSIVLOIWSDFIN-SREVYHEPSA-N 5-[(Z)-2-(4-tert-butylphenyl)ethenyl]-1-(4-propan-2-yloxyphenyl)benzimidazole Chemical compound C1=CC(OC(C)C)=CC=C1N1C2=CC=C(\C=C/C=3C=CC(=CC=3)C(C)(C)C)C=C2N=C1 TVSIVLOIWSDFIN-SREVYHEPSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600036P | 2012-02-17 | 2012-02-17 | |
| US61/600,036 | 2012-02-17 | ||
| PCT/US2013/026173 WO2013123215A2 (fr) | 2012-02-17 | 2013-02-14 | Médicaments antiviraux pour le traitement d'infections à arénavirus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517976A JP2015517976A (ja) | 2015-06-25 |
| JP2015517976A5 true JP2015517976A5 (fr) | 2016-04-07 |
| JP6200903B2 JP6200903B2 (ja) | 2017-09-20 |
Family
ID=48984889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557773A Active JP6200903B2 (ja) | 2012-02-17 | 2013-02-14 | アレナウイルス感染症の治療のための抗ウイルス薬 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9498470B2 (fr) |
| EP (1) | EP2814486B8 (fr) |
| JP (1) | JP6200903B2 (fr) |
| KR (1) | KR101893632B1 (fr) |
| CN (3) | CN104507473A (fr) |
| AP (1) | AP3675A (fr) |
| AU (2) | AU2013221475B2 (fr) |
| BR (1) | BR112014020345B1 (fr) |
| CA (1) | CA2864484C (fr) |
| HK (1) | HK1204949A1 (fr) |
| IL (2) | IL234091A (fr) |
| MX (1) | MX359989B (fr) |
| SG (1) | SG11201404898RA (fr) |
| WO (1) | WO2013123215A2 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101612179B1 (ko) * | 2013-04-19 | 2016-04-12 | 영남대학교 산학협력단 | 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물 |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| WO2018049191A1 (fr) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Dérivés de pyrazolopyridone en tant que modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| WO2018049214A1 (fr) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| WO2019051199A1 (fr) | 2017-09-08 | 2019-03-14 | Incyte Corporation | Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1) |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| WO2019164846A1 (fr) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Dérivés de n-(phényl)-2-(phényl)pyrimidine-4-carboxamide et composés apparentés utilisés en tant qu'inhibiteurs de hpk1 pour le traitement du cancer |
| WO2019164847A1 (fr) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Composés d'indazole et leurs utilisations |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| MA53726A (fr) | 2018-09-25 | 2022-05-11 | Incyte Corp | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| AR117228A1 (es) * | 2018-12-06 | 2021-07-21 | Arisan Therapeutics | DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS |
| WO2020168197A1 (fr) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2 |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223558A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Composés aminés tricycliques en tant qu'inhibiteurs de cdk2 |
| US11066394B2 (en) | 2019-08-06 | 2021-07-20 | Incyte Corporation | Solid forms of an HPK1 inhibitor |
| EP4013750A1 (fr) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Composés imidazolyl-pyrimidinylamines utilisés comme inhibiteurs de la cdk2 |
| WO2021072232A1 (fr) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Amines bicycliques utilisées en tant qu'inhibiteurs de cdk2 |
| CN113234022A (zh) * | 2021-02-05 | 2021-08-10 | 中国人民解放军军事科学院军事医学研究院军事认知与脑科学研究所 | 一种苯并咪唑类衍生物及其合成方法和应用 |
| CN113214161A (zh) * | 2021-02-05 | 2021-08-06 | 中国人民解放军军事科学院军事医学研究院军事认知与脑科学研究所 | 一种具有抗拉沙病毒活性的化合物及其制备方法和应用 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS63157157A (ja) * | 1986-12-22 | 1988-06-30 | Canon Inc | 電子写真感光体 |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| DE3928177A1 (de) * | 1989-04-08 | 1991-02-28 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| JPH0446352A (ja) * | 1990-06-14 | 1992-02-17 | Minolta Camera Co Ltd | 感光体 |
| AU675484B2 (en) * | 1993-03-24 | 1997-02-06 | Neurosearch A/S | Benzimidazole compounds, their use and preparation |
| US5554630A (en) * | 1993-03-24 | 1996-09-10 | Neurosearch A/S | Benzimidazole compounds |
| AU7275894A (en) * | 1993-08-04 | 1995-02-28 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazolylalkylamine derivative and pharmaceutical composition thereof |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| MXPA02005742A (es) * | 2000-01-14 | 2002-09-18 | Schering Ag | 1,2-diaril bencimidazoles para el tratamiento de enfermedades asociadas con la activacion de la micrologia. |
| ATE402164T1 (de) * | 2001-04-26 | 2008-08-15 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
| FR2851248B1 (fr) * | 2003-02-18 | 2005-04-08 | Aventis Pharma Sa | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
| EP1720862A1 (fr) * | 2004-02-03 | 2006-11-15 | Eli Lilly And Company | Inhibiteurs de la kinase |
| DE102005012875B4 (de) * | 2005-03-19 | 2006-11-16 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Amino substituierten 8-N-Benzimidazolen |
| EP1988776B1 (fr) * | 2006-03-02 | 2012-08-08 | Siga Technologies, Inc. | Médicaments antiviraux pour le traitement d'une infection à arénavirus |
| US7977365B2 (en) | 2006-03-02 | 2011-07-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
| CA2672290A1 (fr) * | 2007-01-15 | 2008-07-24 | The United States Of America, As Represented By The Secretary Of The Arm Y, On Behalf Of The U.S. Army Research Institute Of Infectious Diseases | Composes antiviraux et leurs procedes d'utilisation |
| ES2424214T3 (es) * | 2007-08-27 | 2013-09-30 | Siga Technologies, Inc. | Medicamentos antivirales para el tratamiento de una infección por Arenavirus |
| WO2010030360A1 (fr) * | 2008-09-11 | 2010-03-18 | Arena Pharmaceuticals, Inc. | Dérivés 3h-imidazo[4,5-b]pyridin-5-ol utiles dans le traitement de troubles du récepteur gpr81 |
| WO2010121675A2 (fr) * | 2008-12-18 | 2010-10-28 | F. Hoffmann-La Roche Ag | Thiazolyl-benzimidazoles |
| WO2011063293A1 (fr) * | 2009-11-20 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Petites molécules contenant du bore en tant qu'agents antihelminthes |
-
2013
- 2013-02-14 CN CN201380019936.2A patent/CN104507473A/zh active Pending
- 2013-02-14 US US14/379,028 patent/US9498470B2/en active Active
- 2013-02-14 CN CN201910977855.2A patent/CN110698408B/zh active Active
- 2013-02-14 JP JP2014557773A patent/JP6200903B2/ja active Active
- 2013-02-14 KR KR1020147025954A patent/KR101893632B1/ko active IP Right Grant
- 2013-02-14 CA CA2864484A patent/CA2864484C/fr active Active
- 2013-02-14 CN CN201910977868.XA patent/CN110776453A/zh active Pending
- 2013-02-14 WO PCT/US2013/026173 patent/WO2013123215A2/fr active Application Filing
- 2013-02-14 AU AU2013221475A patent/AU2013221475B2/en not_active Ceased
- 2013-02-14 EP EP13749809.3A patent/EP2814486B8/fr active Active
- 2013-02-14 SG SG11201404898RA patent/SG11201404898RA/en unknown
- 2013-02-14 AP AP2014007925A patent/AP3675A/xx active
- 2013-02-14 BR BR112014020345-8A patent/BR112014020345B1/pt not_active IP Right Cessation
- 2013-02-14 MX MX2014009931A patent/MX359989B/es active IP Right Grant
-
2014
- 2014-08-13 IL IL234091A patent/IL234091A/en active IP Right Grant
-
2015
- 2015-06-15 HK HK15105630.8A patent/HK1204949A1/xx not_active IP Right Cessation
-
2016
- 2016-11-16 US US15/353,351 patent/US10000486B2/en active Active
-
2017
- 2017-01-18 AU AU2017200346A patent/AU2017200346B2/en not_active Ceased
- 2017-03-22 IL IL251327A patent/IL251327B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517976A5 (fr) | ||
| JP6200903B2 (ja) | アレナウイルス感染症の治療のための抗ウイルス薬 | |
| JP2017511360A5 (fr) | ||
| JP2018527295A5 (fr) | ||
| SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
| JP2017537949A5 (fr) | ||
| JP2013512903A5 (fr) | ||
| US20060025420A1 (en) | Pharmaceutical compositions for the treatment of female sexual disorders | |
| JP2015505296A5 (fr) | ||
| JP2016525102A5 (fr) | ||
| JP2020532547A5 (fr) | ||
| JP2014511893A5 (fr) | ||
| JP2017537940A5 (fr) | ||
| JP2013502431A5 (fr) | ||
| JP2013518107A5 (fr) | ||
| JP2015514808A5 (fr) | ||
| JP2017527532A5 (fr) | ||
| JP2013510123A5 (fr) | ||
| JP2012524055A5 (fr) | ||
| JP2014511891A5 (fr) | ||
| JP2015522650A5 (fr) | ||
| JP2019526596A5 (fr) | ||
| JP2016505637A5 (fr) | ||
| JP2009502974A5 (fr) | ||
| FI3865484T3 (fi) | Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon |